Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB is set to host a Capital Markets Day in Stockholm on June 4, 2025, as it continues to advance its Phase 2b ADVANCE study for severe rheumatoid arthritis and explores expanding the use of its product, resomelagon, into new indications. This event will provide investors, analysts, and media with insights into the company’s strategic direction and ongoing efforts to enhance its market presence in the biotechnology sector.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company specializing in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory effects in autoimmune and inflammatory diseases, aiding patients in achieving immune balance.
Average Trading Volume: 185,917
Current Market Cap: SEK1.05B
See more data about SYNACT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue